Mylanta

Mylanta is a brand of over-the-counter medicines intended to relieve common digestive symptoms, particularly heartburn, acid indigestion, upset stomach, bloating, and intestinal gas. The brand's portfolio has historically centered on liquid and chewable antacid products, with formulations combining acid-neutralizing ingredients and, in some products, simethicone for gas relief. Depending on the product, active ingredients have included aluminum hydroxide, magnesium hydroxide, calcium carbonate, and simethicone. The brand is associated with the North American consumer-health market and has been sold primarily through pharmacies, supermarkets, mass retailers, and other over-the-counter medicine channels. Its positioning is functional and mass-market: products are marketed around relatively rapid, familiar relief for occasional digestive discomfort rather than as prescription therapies or specialist gastroenterology products. Liquid suspensions have been an important part of the brand identity, while chewable tablets and smaller gas-relief tablets extend the range into portable formats. Mylanta's commercial history has included a significant interruption in availability. In November 2010, liquid Mylanta products were voluntarily recalled after the company identified a labeling issue involving small traces of alcohol in flavoring agents that were not disclosed on the product labeling. The issue concerned disclosure and labeling rather than a reported change in the principal therapeutic purpose of the medicine. The company indicated at the time that it intended to address the problem, and the brand returned to the market in 2016. The brand's manufacturing and licensing arrangements have changed over time. Reference material identifies Infirst Healthcare USA as the manufacturer of Mylanta products under license from McNeil Consumer Healthcare. McNeil is a consumer-health division associated with Kenvue; the business was formerly connected with Pfizer following Pfizer's acquisition of the relevant consumer-health operations in 2007. This structure distinguishes the Mylanta brand from the company that physically manufactures particular products and means that ownership, licensing, and production should not be treated as identical concepts. Current product information cited for the brand includes liquid suspension formulations with combinations such as calcium carbonate, magnesium hydroxide, and simethicone, although exact ingredients and strengths vary by product and market. Mylanta Gas Minis are described as a gas-relief offering containing simethicone in compact tablets, with fruit and mint flavor variants. As with other over-the-counter medicines, formulations, labeling, availability, and marketing authorization can differ over time and should be checked against the product package and applicable regulatory information.

Mylanta developed as a consumer brand for nonprescription treatment of common digestive complaints. Its core proposition has been the combination of antacid relief with products aimed at gas and bloating, allowing the name to cover more than a single medicine format. The principal product forms associated with the brand are liquid suspensions, chewable tablets, and dedicated simethicone gas-relief products. The brand's liquid products have used combinations of acid-neutralizing and anti-gas ingredients. Reference material describes formulations containing calcium carbonate, magnesium hydroxide, and simethicone in specified liquid doses, while other Mylanta products and markets may use different ingredient combinations or strengths. Mylanta Gas Minis are described as compact tablets containing simethicone for immediate gas relief and offered in multiple flavor varieties. Because over-the-counter formulations can be revised, product-specific labeling remains the authoritative source for current ingredients and directions. A major interruption occurred in November 2010, when Mylanta liquid products were voluntarily recalled. The stated concern was that flavoring agents contained small traces of alcohol that had not been disclosed on the label. The event was therefore principally a labeling and disclosure matter. Company sources indicated that corrective work was expected, but the recall affected product availability and generic alternatives became more visible in the market. Mylanta was reintroduced in 2016. The reintroduction restored the brand to the over-the-counter digestive-health category, although availability has not necessarily been uniform across all retailers or markets. The brand's later manufacturing structure is described in reference material as involving Infirst Healthcare USA, which manufactures products under license from McNeil Consumer Healthcare. McNeil is identified as part of Kenvue's consumer-health portfolio; the relevant consumer-health business had previously been associated with Pfizer after its 2007 acquisition. These licensing and manufacturing relationships are important to the brand's corporate history, but the available material does not establish a separate founding date, founder, headquarters, or current named executives for Mylanta itself. Today, Mylanta remains associated with accessible nonprescription relief for heartburn, acid indigestion, upset stomach, bloating, and gas. Its historical strength is the breadth of its digestive-symptom positioning: consumers may encounter the brand in liquid antacid, chewable, or simethicone-focused formats. The available reference material is limited regarding advertising campaigns, international operations, detailed corporate milestones, and present-day leadership, so those areas are left unspecified rather than inferred.

• 2016

  Brand reintroduced

  [1]Mylantaen.wikipedia.org

  Mylanta returned to the market following the earlier recall and period of reduced availability.

• 2010

  Voluntary recall of liquid Mylanta products

  [1]Mylantaen.wikipedia.org

  Liquid Mylanta products were voluntarily recalled in November after undisclosed traces of alcohol were identified in flavoring agents.

• 2007

  Relevant consumer-health business becomes associated with Pfizer

  [1]Mylantaen.wikipedia.org

  Reference material identifies the consumer-health business later associated with Mylanta as having come under Pfizer following an acquisition in 2007.

A mass-market over-the-counter digestive-health brand focused on accessible relief from heartburn, acid indigestion, upset stomach, bloating, and gas.

• Liquid antacid

  Mylanta liquid antacid suspension

  Liquid Mylanta products are suspension-based over-the-counter medicines intended to relieve heartburn, acid indigestion, and related upset-stomach symptoms. Reference material describes one formulation containing calcium carbonate, magnesium hydroxide, and simethicone in a 10 milliliter dose, although ingredients and strengths can vary between products. Multiple flavor options have been associated with the liquid range.

• Chewable antacid

  Mylanta chewable tablets

  Chewable Mylanta products provide a portable solid format for consumers seeking relief from occasional heartburn, acid indigestion, or upset stomach. The available reference material identifies chewable tablets as part of the brand's offering but does not provide a complete current ingredient list, launch date, or market-by-market availability.

• Gas-relief medicine

  Mylanta Gas Minis

  Mylanta Gas Minis are compact tablets intended for relief of gas symptoms. Reference material states that three tablets provide 125 milligrams of simethicone and that the product has been available in assorted fruit and mint flavoring. Exact directions, packaging, and availability should be verified on current product labeling.

• 2016

  Reintroduction of MylantaProduct launch

  Background

  Mylanta had been unavailable or less available following the 2010 voluntary recall.

  Action taken

  The brand was brought back to the market.

  Aftermath

  Mylanta resumed its position in the over-the-counter antacid and gas-relief category.

  Source

• 2010

  Voluntary withdrawal of affected liquid productsOther

  Background

  Small traces of alcohol were found in flavoring agents used in liquid Mylanta products, but the presence was not disclosed on the labeling.

  Action taken

  The company voluntarily recalled the affected liquid products while the labeling concern was addressed.

  Aftermath

  The brand was later reintroduced in 2016, and comparable generic liquid antacids were available during the period of reduced Mylanta availability.

  Source

• 2016

  Mylanta returns to the market[1]Mylantaen.wikipedia.org

  Product launch · Other

  The Mylanta brand was reintroduced to the market after the earlier voluntary recall and period of reduced availability.

• 2010

  Mylanta liquid products voluntarily recalled over labeling concerns[1]Mylantaen.wikipedia.org

  Recall · Regulation

  Mylanta was voluntarily recalled in November 2010 after small traces of alcohol were found in flavoring agents used in liquid antacid products without being disclosed on the labeling. Company statements indicated that the labeling issue would be addressed.

1. 1Mylantaen.wikipedia.org
2. 2NorthStar Sales Alliance Partners with MMCAP Infuseprnewswire.com